Protocol Ledger

NCT06716021 · Phase III · RECRUITING

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

Interventional Phase III clinical trial protocol NCT06716021 sponsored by Milestone Pharmaceuticals in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-20 Enrollment: 750 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06716021
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)750 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06716021
Protocol FieldVerified Registry Value
NCT IdentifierNCT06716021
Consolidated Lead SponsorMilestone Pharmaceuticals
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment750 participants (ESTIMATED)
Registered Start Date2026-08-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06716021
Hospital Research SiteLocationSite Profile
Weill Cornell MedicineNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI